Pharmacokinetic-Pharmacodynamic Analysis of Central & Peripheral Effects of GSK3β Inhibitors

Karin Tunblad1, Erno van Schaick2, Anette Mörtberg1, Karin Agerman1, Susanne Rosqvist1, Per I Arvidsson1, Sandra Visser1

(1) Innovative medicine CNSP AstraZeneca R&D Södertälje, Sweden, (2) Exprimo NV, Zwaanstraatje 4, B-2800 Mechelen, Belgium.

Introduction

Alzheimer’s Disease (AD) is the most common cause of dementia in the elderly. GSK3, a serine/threonine kinase, has been implicated in the aberrant hyperphosphorylation of tau leading to Neurofibrillary Tangles, a key neuropathological hallmark of AD.

Objectives

The aim was to perform a pharmacokinetic-pharmacodynamic analysis of central and peripheral effects of five GSK3 inhibitors in rat pups, and to correlate these effects to in vitro pharmacology measures. And to investigate the influence of plasma protein binding and distribution to the brain.

Data

Each compound was administered at one to three dose levels and the exposure in plasma and in hippocampus was measured at one time-point in each individual. At the same time-point the phosphorylation of Tau in the hippocampus (central biomarker) was measured at two epitopes (AT8 and AT180). Also, the phosphorylation of glycogen synthase in muscle (P-GS) was measured as a peripheral biomarker (Fig1). In vitro pharmacology data, brain binding in adult rat brain and plasma protein binding in rat pup plasma was also available.

Methods and models

For the model building a mixed effects modelling approach was used since there was only one observation of each biomarker per animal. "Individual data" were created by grouping data per study and per compound evaluated giving 21 study/compound combinations. The variability between different study/drug combinations was also evaluated.

The plasma concentrations were used to drive the response and all compounds were simultaneously fitted in one model. The central effects were best described by indirect response models that could account for the delay in onset of this effect, while the peripheral effect was described by a direct effect model.

Translational Opportunity

There was a good correlation between in vitro data and in vivo parameter estimates (Fig 3, right). Also, the IC50 for peripheral and central effects showed a good correlation (Fig 3, left). Correcting for plasma protein binding and distribution to the brain did not change these correlations.

Conclusions & perspectives

The response of the GSK3 inhibitor on P-GS seems to well predict the compound potency for its central effect, although not for the time-course of this effect. This provides a translational opportunity for rat to human extrapolation by characterizing P-GS as a peripheral biomarker in both species (Fig 4). Additionally, the good in vitro-in vivo correlation can be used to benchmark new candidate drugs, showing inhibition of GSK3 in vitro, thereby reducing the need for in vivo screening experiments.